Birzeit Pharmaceuticals Company

PLSE:BPC Stock Report

Market Cap: US$154.7m

Birzeit Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Firas Kathem Nasereddin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure31.7yrs
CEO ownership6.5%
Management average tenureno data
Board average tenure21.3yrs

Recent management updates

Recent updates

CEO

Firas Kathem Nasereddin (54 yo)

31.7yrs

Tenure

US$35,460

Compensation

Mr. Firas Kathem Abdullah Nasereddin is the Chairman and Chief Executive Officer of Grandpharm Pharmaceutical Company, which he founded in 1997. He is Director of the Birzeit Pharmaceutical Company since 2...

Board Members

NamePositionTenureCompensationOwnership
Firas Kathem Nasereddin
Director of Marketing Dept.21.3yrsUS$35.46k6.48%
$ 10.0m
Azzam Shawwa
Directorno datano datano data
Talal Kadhim Nasereddin
Chairman of the Board35yrsUS$35.46k16.78%
$ 26.0m
Farhan Naser Abu Lail Lail
Director34.5yrsUS$35.46kno data
Salem Mostafa Salem Khaizaran
Director13.8yrsUS$35.46kno data
Yahya Mohammad Shawar
Director32.7yrsUS$35.46kno data
Mohammad Hussein Nasereddin
Director1.7yrsno datano data
Rasha Nasereddin
Director2.1yrsno datano data

21.3yrs

Average Tenure

61yo

Average Age

Experienced Board: BPC's board of directors are seasoned and experienced ( 21.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 19:40
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Birzeit Pharmaceuticals Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution